LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

4.04

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.99

Максимум

4.15

Ключови измерители

By Trading Economics

Приходи

4.1M

-5.7M

Служители

34

EBITDA

3.1M

-6.8M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+408.91% upside

Дивиденти

By Dow Jones

Следващи печалби

12.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-24M

364M

Предишно отваряне

4.04

Предишно затваряне

4.04

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.02.2026 г., 22:31 ч. UTC

Печалби

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18.02.2026 г., 22:18 ч. UTC

Печалби

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18.02.2026 г., 22:11 ч. UTC

Печалби

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18.02.2026 г., 21:52 ч. UTC

Печалби

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18.02.2026 г., 23:56 ч. UTC

Пазарно говорене

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

18.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18.02.2026 г., 23:34 ч. UTC

Пазарно говорене
Печалби

Brambles' Cost Control Stands Out to Bull -- Market Talk

18.02.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18.02.2026 г., 23:32 ч. UTC

Пазарно говорене

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18.02.2026 г., 22:45 ч. UTC

Печалби

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18.02.2026 г., 22:44 ч. UTC

Пазарно говорене

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18.02.2026 г., 22:37 ч. UTC

Печалби

Nutrien 4Q EPS $1.18 >NTR.T

18.02.2026 г., 22:37 ч. UTC

Печалби

Nutrien 4Q Sales $5.34B >NTR.T

18.02.2026 г., 22:35 ч. UTC

Печалби

Pan American Silver 4Q EPS $1.07 >PAAS

18.02.2026 г., 22:35 ч. UTC

Печалби

Pan American Silver 4Q Rev $1.18B >PAAS

18.02.2026 г., 22:30 ч. UTC

Печалби

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18.02.2026 г., 22:29 ч. UTC

Печалби

Kinross Gold 4Q EPS 75c >K.T

18.02.2026 г., 22:22 ч. UTC

Печалби

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18.02.2026 г., 22:22 ч. UTC

Пазарно говорене

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18.02.2026 г., 22:16 ч. UTC

Печалби

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18.02.2026 г., 22:05 ч. UTC

Печалби

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18.02.2026 г., 22:03 ч. UTC

Печалби

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18.02.2026 г., 22:02 ч. UTC

Печалби

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18.02.2026 г., 22:02 ч. UTC

Печалби

Kaiser Aluminum 4Q Sales $929M >KALU

18.02.2026 г., 22:02 ч. UTC

Печалби

Kaiser Aluminum 4Q EPS $1.68 >KALU

18.02.2026 г., 22:00 ч. UTC

Печалби

Kinross Gold 4Q Adj EPS 67c >KGC

18.02.2026 г., 22:00 ч. UTC

Печалби

Kinross Gold 4Q Sales $2.02B >KGC

18.02.2026 г., 21:56 ч. UTC

Печалби

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

408.91% нагоре

12-месечна прогноза

Среден 20 USD  408.91%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat